ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
October 18, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET - First patient in global, 300-patient Phase 2b study of ASLAN004 on track for enrolment...
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology
October 14, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
September 27, 2021 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p<0.0251) versus...
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield
September 21, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 06, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis Topline,...
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
August 04, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
July 13, 2021 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare Conference
May 25, 2021 07:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, May 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives...